Home

Training My Thoughts

Rode the train up to DC from Charlottesville on Friday night and, let me tell you, despite all the years and money thrown at...

enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial

TW's Take: we believe the VenoValve will be a rapidly adopted and a very big product if and when it gets approved. The market...

Amryt Announces New Patents for Oleogel-S10 and Mycapssa®

TW's Take: nice to see these patents issued. More importantly, however, we are approaching the PDUFA date for Oleogel. With AMYT languishing around $12,...

Saturday Morning Musings

In a slow week for news from our universe of companies, the biggest news was from TFF Pharma (TFFP) which announced pre-clinical success of...

Why TFF’s Hamster Data Is Bigger Than Investors Think

As the Delta variant of Covid-19 has demonstrated quite clearly, despite the success of the vaccine programs, the virus is here to stay. Getting...

Trading Blog, October 14th, 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation...

TW's Take: very bullish news. This is the first dry powder (inhalable) treatment to show positive results. It also validates the mAb platform as...

Ondas Holdings Inc. Announces Strategic Partnership with Dynam.AI

NANTUCKET, MA / ACCESSWIRE / October 11, 2021 / Ondas Holdings Inc. (NASDAQ:ONDS), a leading provider of private wireless data and automated data solutions through...

$8 Paddle Balls?

The markets had a nice bounce late last week. This was sparked by the government getting its act together enough to kick the debt...

Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented...

TW's Take: another significant positive for Fortress, which owns 72% of Cyprium. They also qualify for a Priority Review Voucher, worth roughly $100M. NIH...

LexaGene’s Largest Study Validates Accuracy of its Veterinary Test Panel

Technology Accurately Identifies Pathogens and Predicts Antimicrobial Resistance In less than 30 years, drug resistant bacteria are predicted to kill 3 times more people...

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

TW's Take: patent protection in China is an unexpected surprise. We are looking forward to seeing the company begin both their human trials during...

Trading Blog, October 5th, 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

October Awaits

September to remember? I had such high hopes. Sadly, it turned out to be a very forgettable month and I'm happy to have it...

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

TW's Take: a positive that this patent helps broaden coverage of the technology in other cancers besides ovarian. If this CAR-T therapy proves effective,...

LexaGene Reports on Recent Veterinary Trade Shows

TW's Take: the veterinary market is an underserved, and underappreciated by investors, arena that can drive LexaGene's business over time as we await progress...

Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire...

TW's Take: This provides Fortress with over $60 million in immediate cash and potentially close to another $150 million in milestones. That's around 60%...

Trading Blog, Sept. 28th, 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

Lantern Pharma Enters into Strategic Collaboration with Deep Lens — Partnership Expected to Accelerate...

TW's Take: Lantern continues to be on the leading edge of combining A.I. and oncology drug development. This partnership should help them not only...

Cash is King

After several weeks of lower stock prices, the market this past week decided that the looming bankruptcy of the world's largest real estate debt...

Become a TW Research Member

All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.

For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $500 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.

SIGN ME UP

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.